JMIR Cancer

Patient-centered innovations, education, and technology for cancer care, cancer survivorship, and cancer research.

Editor-in-Chief:

Naomi Cahill, PhD, RD, Editor-in-Chief; Scientific Editor at JMIR Publications, Canada


Impact Factor 3.3 CiteScore 4.1

JMIR Cancer (JC, ISSN: 2369-1999) is a peer-reviewed journal focusing on education, innovation and technology in cancer care, cancer survivorship and cancer research, and participatory and patient-centred approaches. This journal also includes research on non-Internet approaches to improve cancer care and cancer research.

We invite submissions of original research, viewpoints, reviews, tutorials, case studies, and non-conventional articles (e.g. open patient education material and software resources that are not yet evaluated but are free for others to use/implement). 

In our "Patients' Corner," we invite patients and survivors to submit short essays and viewpoints on all aspects of cancer. In particular, we are interested in suggestions on improving the health care system and suggestions for new technologies, applications and approaches (this section has no article processing fees).

In 2024, JMIR Cancer received a Journal Impact Factor™ of 3.3 (Source: Journal Citation Reports™ from Clarivate, 2024). JMIR Cancer is indexed in PubMed Central and PubMedScopusDOAJ, MEDLINE, and the Emerging Sources Citation Index (Clarivate). With a CiteScore of 4.1, JMIR Cancer is a Q2 journal in the field of Oncology, according to Scopus data.

Recent Articles

Article Thumbnail
Emotional, Social, Psychological Support for Cancer

Psychological distress (PD) is a common mental health problem faced by caregivers of children with cancer. The involvement of families in childcare was found to be associated with lower levels of distress.

|
Article Thumbnail
Innovations and Technology for Cancer Prevention and Screening

The need for increased clinical efficacy and efficiency has been the main force in developing artificial intelligence (AI) tools in medical imaging. The INCISIVE project is a European Union–funded initiative aiming to revolutionize cancer imaging methods using AI technology. It seeks to address limitations in imaging techniques by developing an AI-based toolbox that improves accuracy, specificity, sensitivity, interpretability, and cost-effectiveness.

|
Article Thumbnail
Cancer Self-Management

Family caregivers of individuals with gynecologic cancer experience high levels of distress. Web-based caregiver support interventions have demonstrated efficacy in improving caregiver outcomes. However, the lack of portability could be a limitation. Mobile health (mHealth) apps could fill this gap and facilitate communication between patient-caregiver dyads.

|
Article Thumbnail
Cancer Prognosis Models and Machine Learning

Salvage radiation therapy (sRT) is often the sole curative option in patients with biochemical recurrence after radical prostatectomy. After sRT, we developed and validated a nomogram to predict freedom from biochemical failure.

|
Article Thumbnail
Viewpoints and Perspectives

Oral chemotherapy is commonly prescribed, and by using decision aids (DAs), clinicians can facilitate shared decision-making (SDM) to align treatment choices with patient goals and values. Although products exist commercially, little evidence informs the development of DAs targeting the unique challenges of oral chemotherapy. To address this gap in the literature, our objective was to review DAs developed for oral anticoagulation, DA use in oncology, and patient preference surveys to guide the development of DAs for oral chemotherapy. We focused on reviewing SDM, patient preferences, and specifically the development, efficacy, and patient experience of DAs in oral anticoagulation and oncologic conditions, ultimately including conclusions and data from 30 peer-reviewed publications in our viewpoint paper. We found that effective DAs in oral anticoagulation improved knowledge, lowered decisional conflict, increased adherence, and covered a broad range of SDM elements; however, limited information on patient experience was a common shortcoming. In oncology, DAs increased knowledge and aligned decisions with the values of the patients. Ineffective oncology DAs provided general, unclear, or overly optimistic information, while providing “too much” information was not shown to do harm. Patients preferred DAs that included pros and cons, side effects, questions to ask, and expected quality of life changes. In developing DAs for oral chemotherapy, patients should be included in the development process, and DA content should be specifically tailored to patient preferences. Providing DAs ahead of appointments proved more effective than during, and additional considerations included addressing barriers to efficacy. There is a need for evidence-based DAs to facilitate SDM for patients considering oral chemotherapy. Developers should use data from studies in oral anticoagulation, oncology, and preference surveys to optimize SDM.

|
Article Thumbnail
Innovations and Technology in Cancer Care

Patients with prostate cancer undergoing radiation therapy (RT) need comfortably full bladders to reduce toxicities during treatment. Poor compliance is common with standard of care written or verbal instructions, leading to wasted patient value (PV) and clinic resources via poor throughput efficiency (TE).

|
Article Thumbnail
Reviews on Innovations in Cancer

Cancer is a significant public health issue worldwide. Treatments such as surgery, chemotherapy, and radiation therapy often cause psychological and physiological side effects, affecting patients’ ability to function and their quality of life (QoL). Physical activity is crucial to cancer rehabilitation, improving physical function and QoL and reducing cancer-related fatigue. However, many patients face barriers to accessing cancer rehabilitation due to socioeconomic factors, transportation issues, and time constraints. Telerehabilitation can potentially overcome these barriers by delivering rehabilitation remotely.

|
Article Thumbnail
Cancer Prognosis Models and Machine Learning

The treatment of acute myeloid leukemia (AML) in older or unfit patients typically involves a regimen of venetoclax plus azacitidine (ven/aza). Toxicity and treatment responses are highly variable following treatment initiation and clinical decision-making continually evolves in response to these as treatment progresses. To improve clinical decision support (CDS) following treatment initiation, predictive models based on evolving and dynamic toxicities, disease responses, and other features should be developed.

|
Article Thumbnail
Nutrition, Physical Activity, Healthy Lifestyle for Cancer Patients and Survivors

Physical activity engagement following a cancer diagnosis is positively associated with survival, reduced risk of disease recurrence, and reduced cancer-specific and all-cause mortality. However, rates of physical activity engagement are low among individuals diagnosed with and being treated for breast cancer or prostate cancer.

|
Article Thumbnail
Health Services Research in Oncology

Complementary and alternative (CAM) cancer treatment is often expensive and not covered by insurance. As a result, many people turn to crowdfunding to access this treatment.

|

Preprints Open for Peer-Review

There are no preprints available for open peer-review at this time. Please check back later.

We are working in partnership with